Consolidated balance sheet
|
in CHF 1 000 |
|
Notes |
|
30.06.2022 |
|
31.12.2021 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
1 724 |
|
2 835 |
|
Securities |
|
4 |
|
2 852 415 |
|
3 641 112 |
|
Other assets |
|
|
|
163 |
|
135 |
|
|
|
|
|
2 854 302 |
|
3 644 082 |
|
Total assets |
|
|
|
2 854 302 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
326 000 |
|
355 000 |
|
Payables to brokers |
|
|
|
4 640 |
|
– |
|
Other short-term liabilities |
|
|
|
3 729 |
|
5 431 |
|
Tax liabilities |
|
|
|
93 |
|
158 |
|
|
|
|
|
334 462 |
|
360 589 |
|
Total liabilities |
|
|
|
334 462 |
|
360 589 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
6 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
6 |
|
(27 689) |
|
(9 205) |
|
Retained earnings |
|
|
|
2 536 449 |
|
3 281 618 |
|
|
|
|
|
2 519 840 |
|
3 283 493 |
|
Total liabilities and shareholders' equity |
|
|
|
2 854 302 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
45.80 |
|
59.40 |
The notes are an integral part of the condensed consolidated interim financial statements.
The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on July 19, 2022.